Successful pulmonary administration of activated recombinant factor VII in diffuse alveolar hemorrhage by Heslet, Lars et al.
Open Access
Available online http://ccforum.com/content/10/6/R177
Page 1 of 6
(page number not for citation purposes)
Vol 10 No 6 Research
Successful pulmonary administration of activated recombinant 
factor VII in diffuse alveolar hemorrhage
Lars Heslet1, Jorn Dalsgaard Nielsen2, Marcel Levi3, Henrik Sengeløv4 and Pär I Johansson5
1Department of Intensive Care ITA 4131, University Hospital of Copenhagen, Rigshospitalet, Blegdamsvej 9, DK 2100 Denmark
2Department of Clinical Biochemistry, Gentofte University Hospital, Niels Andersens Vej 65, DK 2900 Hellerup, Denmark
3Department of Internal Medicine/Vascular Medicine, Amsterdam Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
4Department of Hematology H, University Hospital of Copenhagen, Rigshospitalet, Blegdamsvej 9, DK 2100 Denmark
5Department of Clinical Immunology, University Hospital of Copenhagen, Rigshospitalet, Blegdamsvej 9, DK 2100 Denmark
Corresponding author: Lars Heslet, heslet@rh.dk
Received: 5 Oct 2006 Revisions requested: 9 Nov 2006 Revisions received: 5 Dec 2006 Accepted: 21 Dec 2006 Published: 21 Dec 2006
Critical Care 2006, 10:R177 (doi:10.1186/cc5132)
This article is online at: http://ccforum.com/content/10/6/R177
© 2006 Heslet et al.; licensee BioMed Central Ltd. 
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Introduction Diffuse alveolar hemorrhage (DAH) is a serious
pulmonary complication seen in patients with autoimmune
disorders and patients treated with chemotherapy or after
hematopoietic stem cell transplantation. The clinical
management of DAH is complex and the condition has a high
mortality rate. Tissue factor is expressed in the lung alveoli
during inflammation and therefore pulmonary administration of
human recombinant activated factor VIIa (rFVIIa) could be a
rational treatment option.
Methods Six patients with acute, bronchoscopically confirmed
DAH from a single intensive care unit university hospital center
were included in the study of acute DAH in critically ill patients.
The patients were treated with intrapulmonary administration of
50 μg/kg rFVIIa in 50 ml of sodium chloride by bronchoalveolar
lavage (BAL) with 25 ml in each of the main bronchi, which was
repeated after 24 hours in case of treatment failure.
Results An excellent response, defined as complete and
sustained hemostasis after a single dose of rFVIIa, was seen in
three patients. A good response, meaning that sustained
hemostasis was achieved by a repeated rFVIIa administration,
was seen in the remaining three patients. In one of these
patients, the BAL treatment was repeated twice; in another
patient, the second dose of rFVIIa was administered by nebulizer
after extubation after the initial BAL. The hemostatic effect was
statistically significant (p = 0.031). The oxygenation capacity, as
reflected by the PaO2/FiO2 (arterial oxygen pressure/inspiratory
fractional oxygen content) ratio, increased significantly (p  =
0.024) in all six patients following the local rFVIIa therapy.
Conclusion Symptomatic therapy of DAH after intrapulmonary
administration of one or more doses of rFVIIa was found to have
a good to excellent hemostatic effect in six consecutive patients
with DAH. The intrapulmonary administration of rFVIIa seemed
to have a high benefit-to-risk ratio. Larger series should confirm
the safety of this approach.
Introduction
Diffuse alveolar hemorrhage (DAH) is a serious pulmonary
complication of mostly unknown etiology and pathogenesis,
although injury to alveolar capillary endothelium and alveolar
inflammation, resulting in the release of inflammatory
cytokines, have been implicated [1,2]. The disease is seen
after hematopoietic stem cell transplantation (HSCT), after
chemotherapy, and in patients with autoimmune disorders [3].
The extensive pulmonary inflammation leads to abundant intra-
alveolar expression of tissue factor (TF), resulting in a several-
fold increase in molecular markers of thrombin generation in
bronchoalveolar lavage (BAL) fluid [4]. Effective local hemo-
static strategies are lacking, and mortality rates exceed 50%
in those who require mechanical ventilator support [5]. We
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hypothesized that local administration of human recombinant
activated factor VIIa (rFVIIa) might be an effective treatment
option.
Materials and methods
Six consecutive patients with pulmonary bleeding, of whom
four had an inspiratory fractional oxygen content (FiO2)
demand of 1.0, not responding to conventional therapy were
studied. At our institution, treatment of pulmonary bleeding
includes transfusion of fresh frozen plasma (FFP) and platelet
concentrate (PC) to normalize systemic coagulation ability,
endotracheal and intravenous (i.v.) administration of tran-
examic acid, and if no hemostatic effect is obtained, this is fol-
lowed by continuous aprotinin i.v. infusion. The diagnosis of
DAH was confirmed bronchoscopically by identification of
ongoing bleeding at the bronchial segmental level before treat-
ment with rFVIIa. The dose was approximately 50 μg/kg dis-
solved in 50 ml of saline distributed evenly in the right and left
main bronchi. In one non-intubated patient, rFVIIa was admin-
istered as an inhalant at a dose of 50 μg/kg via a jet-driven
nebulizer.
Treatment efficacy of rFVIIa was graded as an excellent, good,
or poor response. An 'excellent' response was defined as a
complete and sustained hemostasis after a single treatment
with rFVIIa. The response was graded as 'good' when
repeated intrapulmonary administration of rFVIIa was required
to obtain hemostasis. A 'poor' response was characterized by
the lack of any effect by rFVIIa on bleeding. The hemostatic
effect and the oxygenation capacity were statistically analyzed
using the non-parametric tests, McNemar's test and Wilcoxon
signed paired rank test, respectively. A waiver of informed con-




A 46-year-old male with chronic lymphocytic leukemia under-
went allogenic non-myeloablative stem cell transplantation
(HSCT). The post-transplant course was complicated by
severe graft-versus-host disease (GvHD) of the skin, thrombo-
cytopenia, and systemic cytomegalovirus (CMV) infection,
causing treatment-induced renal failure that necessitated
hemodialysis (Table 1).
Nine months after HSCT, he was admitted to the intensive
care unit (ICU) with septic shock, which was treated with
empiric antibiotics, vasoactive medication, and mechanical
ventilation. Seven days after ICU admission, the FiO2 require-
ment suddenly increased to 1.0 and fresh blood was coming
from the endotracheal tube. The platelet count was 10 × 109
per liter and the activated partial thromboplastin time (APTT)
was 40 seconds. Despite platelet transfusion to a platelet
count of more than 100 × 109 per liter and FFP administration
to an APTT of less than 35 seconds (in addition to the stand-
ard treatment as described in Materials and methods), the
bleeding increased in severity. rFVIIa was administered intra-
venously in doses of up to 120 μg/kg without hemostatic
effect. Bronchoscopy revealed fresh bleeding from both lungs.
rFVIIa (50 μg/kg) dissolved in saline was administered by BAL
into the left and right main bronchi simultaneously with the sys-
temic i.v. administration of 50 μg/kg rFVIIa. This resulted in an
immediate cessation of the bleeding from the endotracheal
tube. The arterial oxygen pressure (PaO2)/FiO2 ratio increased
the subsequent day. The hemostatic effect lasted for approxi-
mately 36 hours, after which bleeding recurred. The treatment
was repeated twice also, and bleeding ceased for more than
24 hours. Hereafter, the patient received rFVIIa (50 μg/kg) by
BAL alone twice, and bleeding ceased for 24 to 36 hours after
each administration. Complete hemostasis was obtained after
the third BAL administration of rFVIIa and lasted for three
months (Table 2). The patient died three months after the first
rFVIIa treatment, due to respiratory and circulatory failure
secondary to septic shock without evidence of active pulmo-
nary bleeding. Postmortem examination revealed no signs of
acute respiratory distress syndrome (ARDS) in the alveoli or
thromboembolic complications.
Table 1
Comparison of underlying disease, the effect of intrapulmonary rFVIIa therapy, and survival of DAH
Patient Gender Diagnosis Pathogenesis of DAH rFVIIa doses via BAL Evaluation of rFVIIa effecta Survival or cause of death
1 Male Allo-HSCTb (CLL) CMV, GvHD 3 Good Septic shock and cardiorespiratory 
failure
2 Male Neurosarcoidosis Unknown 1 Excellent Septic shock
3 Male AML Unknown 1 Excellent Survived
4 Female Wegener's granulomatosis Unknown 1c Good Survived
5 Female AIDS Unknown 2 Good Septic shock and respiratory failure
6 Male Allo-HSCT (AML) Unknown 1 Excellent Survived
aThe hemostatic effect was statistically significant (p = 0.031, McNemar's test). bNon-myeloablative allogeneic stem cell transplantation. cOne 
rFVIIa dose via BAL and, three days later when not intubated, subsequent three consecutive doses of rFVIIa via jet nebulizer. AML, acute myeloid 
leukemia; BAL, bronchoalveolar lavage; CLL, chronic lymphatic leukemia; CMV, cytomegalovirus; DAH, diffuse alveolar hemorrhage; GvHD, graft-
versus-host disease; HSCT, hematopoietic stem cell transplantation; rFVIIa, human recombinant activated factor VII.Available online http://ccforum.com/content/10/6/R177
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Patient 2
A 63-year-old male with progressive neurosarcoidosis was
treated with infusion of methotrexate. After the second treat-
ment, he developed pancytopenia and septic shock and was
transferred to the ICU, where he was intubated and mechani-
cally ventilated. Fresh blood was observed from the tracheal
tube, and chest x-ray showed interstitial diffuse alveolar infil-
trates indicating pulmonary bleeding. Standard treatment was
instituted, resulting in an increase in platelet count from 18 ×
109 per liter to 88 × 109 per liter with a reduction in APTT from
45 to 36 seconds (Table 2). Multiple organ failure developed
and increasing amounts of fresh blood were observed from the
tube while the FiO2 requirement increased from 0.7 to 1.0. A
single dose (20 μg) of i.v. desmopressin did not improve
hemostasis. Bronchoscopy revealed ongoing bleeding from
the distal bronchial tree bilaterally. A 50 μg/kg dose of rFVIIa
was administered via BAL, resulting in immediate cessation of
the pulmonary bleeding. Four hours after rFVIIa administration,
FiO2 could be reduced to 0.8 and was further reduced to 0.6
the following morning (Table 2). Despite continued improve-
ment in pulmonary function, increasing circulatory instability
secondary to septic shock became evident and the patient
died four days after rFVIIa treatment. No pulmonary bleeding
or thromboembolic complications were found after the
intrapulmonary administration of rFVIIa.
Patient 3
A 44-year-old male with acute myeloid leukemia (AML) devel-
oped high fever and hemoptysis 14 days after induction of a
combination of chemotherapy comprising cytarabine, amsa-
crine, and etoposide. Chest x-ray showed bilateral infiltrations,
and BAL revealed Stenotrophomonas maltophilia. The patient
was admitted to the ICU, where mechanical ventilation was
instituted with an FiO2 of 1.0, and was started with inotropic
support and antimicrobial therapy (i.v. ceftazidime and inhala-
tion of colistin). Pulmonary bleeding increased despite stand-
ard treatment (Table 2). Bronchoscopy revealed ongoing
bleeding from the distal bronchial tree bilaterally, and rFVIIa
(50 μg/kg) was administered by BAL. The bleeding ceased
and the FiO2 was decreased to 0.45 over the next 24 hours.
Over the next 12 days, the situation stabilized and improve-
ment of the pulmonary and the circulatory functions was
observed and the patient could be weaned off of the ventilator
and discharged from the ICU. No pulmonary bleeding or
thromboembolic complications were observed after the
intrapulmonary administration of rFVIIa.
Patient 4
A 34-year-old woman was suspected of having Wegener's
granulomatosis on the basis of eosinophilia, positive anti-neu-
trophil cytoplasmatic antibodies, hematuria, and proteinuria.
Treatment with systemic corticosteroids was instituted, but
due to respiratory distress and the presence of hemoptysis,
the patient was admitted to the ICU. Chest x-ray showed inter-
stitial subtle bilateral alveolar infiltrates indicating pulmonary
bleeding. The patient was intubated and mechanically venti-
lated with an FiO2 of 1.0, and systemic antibiotic treatment
was initiated in conjunction with pulse treatment with methyl-
prednisone (1,000 mg intravenously every day for three days
and then 40 mg every day). Treatment including continuous
aprotinin infusion was instituted. The pulmonary bleeding
ceased, FiO2 demand was reduced to 0.35, and antifibrinolytic
treatment was discontinued. Twelve hours after discontinua-
tion of aprotinin, fresh pulmonary bleeding again became
apparent, together with an increase in FiO2 requirements to
1.0. The bleeding was refractory to standard treatment, includ-
ing aprotinin. Bronchoscopy revealed ongoing bleeding at the
segmental level, and rFVIIa (50 μg/kg) was administered by
BAL, leading to immediate cessation of the bleeding; FiO2 was
reduced to 0.3 at six hours after rFVIIa treatment, and the
patient was extubated the following morning.
A biopsy from the skin showed perivascular eosinophilic infil-
tration indicating Churg-Strauss vasculitis, and the patient
Table 2
Comparison of hemostatic variables and oxygenation capacity before and after rFVIIa in patients with DAH
Timing 24 hours prior to rFVIIa 24 hours after rFVIIaa
P a t i e n t  n u m b e r 1 2 3456 1 b 23456
Coagulation Platelet count (109 per liter) 110 88 112 105 99 90 100 80 106 105 102 69
A P T T  ( s e c o n d s ) 3 1 3 6 3 23 34 12 73 33 83 23 33 82 7
T r a n s f u s i o n  ( u n i t s ) R B C s 4 3 2434100412
F F P 4 2 2222000200
P C 2 2 2221000200
Oxygenation capacity PaO2/FiO2 ratio (mm Hg) 67 62 88 64 187 100 176 152 132 313 213 345
aThe increase in oxygenation capacity was significant (p = 0.024, Wilcoxon signed paired rank test). bThere was a steady increase in oxygenation 
capacity subsequent to rFVIIa therapy (that is, the PaO2/FiO2 ratio was 176 mm Hg after one day, 137 mm Hg after one month, 136 mm Hg after 
two months, and finally 252 mm Hg after three months). APTT, activated partial thromboplastin time; DAH, diffuse alveolar hemorrhage; FFP, fresh 
frozen plasma; PaO2/FiO2, arterial oxygen pressure/inspiratory fractional oxygen content; PC, platelet concentrate; RBC, red blood cell; rFVIIa, 
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responded to the corticosteroid therapy treatment with regres-
sion of paresis and normalization of urine tests. Three days
after extubation, bleeding from the lungs reoccurred together
with an increase in O2 demand. To avoid re-intubation, rFVIIa
was administered through a jet nebulizer with a prompt hemo-
static effect. The aerosolized rFVIIa was repeated twice over
the following 12 hours. A sustained hemostasis and a
decrease in O2 requirements from 15 to 4 liters/minute were
obtained. The further clinical course was uneventful, and the
patient was discharged from the ICU three days later.
Patient 5
A 44-year-old HIV-positive female with chronic hemodialysis
requirement, severe critical illness polyneuropathy, and entero-
colitis due to Clostridium  difficile  infection, for which she
received i.v. vancomycin, underwent surgery due to gastroin-
testinal bleeding. Postoperatively, she was transferred to the
ICU, receiving mechanical ventilator support, and developed
ventilator-associated pneumonia due to Pseudomonas aerugi-
nosa, which was treated successfully with broad-spectrum
antibiotics. In addition, a systemic CMV infection developed
for which she was treated with Foscarnet, leading to stabiliza-
tion over the following weeks. At 51 days after ICU admission,
however, fresh bleeding occurred from the tracheotomy but
did not respond to standard treatment as described previ-
ously. BAL revealed localized bleeding at the segmental level
bilaterally, and rFVIIa (50 μg/kg) dissolved in 50 ml of sodium
chloride was administered with 25 ml in each main bronchus.
The pulmonary bleeding ceased but reappeared within 24
hours after the treatment, and rFVIIa administration by BAL
was repeated. Hereafter, the bleeding ceased to occur. The
patient expired due to infection and respiratory insufficiency
115 days after rFVIIa treatment, without any signs of throm-
boembolic complications.
Patient 6
A 63-year-old male with AML underwent non-myeloablative
stem cell transplantation. The post-transplant course was
complicated by GvHD of the skin and temporary poor graft
function with pancytopenia. Six months post-transplant, the
patient was transferred to the ICU due to respiratory insuffi-
ciency secondary to pulmonary infection. The patient was intu-
bated and mechanically ventilated with an FiO2  of 0.45.
Diagnostic BAL showed fresh blood at segmental levels bilat-
erally, but the focus of bleeding could not be identified. The
platelet count was 35 × 109 per liter and APTT was 40 sec-
onds, for which the patient received FFP to achieve an APTT
of less than 30 seconds and PCs to achieve a platelet count
of more than 80 × 109 per liter but without significant effect on
the bleeding. The patient received empirical broad-spectrum
antibiotics and antimycotics, resulting in a decrease of the C-
reactive protein over the next five days. Twelve days after ICU
admission, the pulmonary bleeding increased and the FiO2
demand was increased to 0.6. The patient had a normal TEG
(thrombelastografic  in vitro coagulation) profile, a platelet
count of 80 × 109 per liter, and an APTT of 27 seconds, indi-
cating a localized coagulopathy. Due to further increase in
bleeding and FiO2 demand, a diagnostic BAL was performed,
showing fresh bleeding bilaterally at segmental levels; rFVIIa at
a dose of 50 μg/kg dissolved in 50 ml of saline was adminis-
tered, resulting in immediate cessation of the pulmonary
bleeding. The FiO2 was reduced to 0.35 within the next eight
hours, and the patient was extubated the following morning.
Three days after treatment with local pulmonary rFVIIa, the
patient was discharged from the ICU without further bleeding
episodes.
Discussion
DAH is a clinical syndrome with acute onset of alveolar infil-
trates and hypoxemia, yielding progressively diffuse alveolar
bleeding. Clinical features include dyspnea, cough, hemopty-
sis, abnormal chest x-ray with bilateral alveolar infiltrates, and
hypoxia usually accompanied with fever [6,7]. The treatment of
DAH is empiric in as much as the condition is a life-threatening
medical emergency with no specific or proven effective ther-
apy. Treatment with high-dose steroids may be beneficial
when given early [7], but overall mortality remains high; plas-
mapheresis has been advocated, but there is no evidence that
this intervention is successful in the treatment of ongoing low-
volume critical bleeding [8].
Here, we report a series of six patients of DAH verified by bron-
choscopy in mechanically ventilated patients. There was no or
insufficient hemostatic effect of standard therapy including
transfusion of FFP and PCs, i.v. infusion of aprotinin, and tran-
examic acid intravenously or via the endotracheal route (Table
1).
rFVIIa is an approved agent for the i.v. treatment of bleeding
episodes in patients with hemophilia A or B with inhibiting anti-
bodies toward factor VIII or factor IX, respectively. Factor VII
initiates clot formation by its interaction with TF [9,10]. The
FVIIa-TF complex activates factor X. In high doses (80 to 100
μg/kg), however, activated FVII also activates factor X in the
absence of TF, probably by activation of factor X bound to the
surface of activated platelets. Activated factor X activates pro-
thrombin to thrombin, which in turn converts fibrinogen to fibrin
[10].
High and repeated i.v. doses of rFVIIa have been reported to
have some hemostatic effect in patients with DAH [11-13]. As
described in this report, however, i.v. administration of a very
high dose of rFVIIa did not induce hemostasis in our first
patient with DAH. This led us to explore the effect of local pul-
monary administration of rFVIIa, and the efficacy of this
treatment was demonstrated in six consecutive patients with
DAH of different etiologies. The rFVIIa was administered at a
dose of approximately 50 μg/kg via BAL in six patients and as
a nebulized aerosol on one occasion. The intervention with
local intrapulmonary rFVIIa had a significant hemostatic effectAvailable online http://ccforum.com/content/10/6/R177
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(p = 0.031). To our knowledge, this is the first time an effective
treatment of DAH using symptomatic treatment with local
intrapulmonary rFVIIa has been reported.
Clinical observation supports the hypothesis that pulmonary
hemostasis can be induced more effectively from the alveolar
side in DAH and than from the endothelial side. This viewpoint
is supported by the fact that alveolar TF is demonstrated in
high concentrations in inflammatory pulmonary conditions like
ARDS [14], pneumonia [15], and after lipopolysaccharide
challenge locally in the alveoli [16]. The mode of action of the
observed alveolar hemostasis is most likely primarily explained
by the TF-dependent pathway, where alveolar TF is expressed
during the inflammatory phase of DAH. On the other hand, TF
pathway inhibitor (TFPI) is a strong inhibitor of the local activa-
tion of factor X to Xa by the FVIIa-TF complex. In acute lung
injury, TFPI produced by alveolar macrophages may be
increased 20-fold [17]. Our observations indicate that
intrapulmonary administration of FVIIa overrides the anticoag-
ulant effect of TFPI (Figure 1).
A safety issue of the local rFVIIa treatment, however, is the
possible risk of inducing widespread alveolar fibrin deposition
(that is, hyaline membrane formation), which is a hallmark of
ARDS. There were, however, no signs of developing ARDS in
the six treated patients because the oxygenation capacity, as
reflected by the PaO2/FiO2 ratio, increased significantly in the
six patients after the pulmonary rFVIIa administration (Figure
2). The benefit, the hemostatic effect, was excellent in three
patients and good in three patients (that is, a statistically sig-
nificant treatment effect was observed in all patients) (Table
2). The benefit-to-risk ratio of local rFVIIa treatment in DAH
therefore seems to be high.
Conclusion
A new symptomatic therapy, involving intrapulmonary adminis-
tration of rFVIIa, to stop the life-threatening critical bleeding in
DAH is documented in six consecutive patients with DAH. It
seems that pulmonary hemostasis occurs most likely from the
alveolar side in DAH and to a much lesser extent from the lung
vascular endothelial side, a viewpoint that is supported by the
clinical observation of the patients with DAH and by the well-
described pathophysiology of the lung as a hemostatic organ,
with TF-dependent and TF-independent modes of action. But
irrespective of the mode of action, FVIIa has a potentially high
benefit-to-risk ratio when administered via the local intrapulmo-
nary route. These findings warrant further exploration of the
local pulmonary effect of rFVIIa and the safety of this novel
treatment strategy in patients with DAH.
Figure 1
Rationale for the local mode of action of intra-alveolar human recom- binant activated factor VII (rFVIIa) in diffuse alveolar hemorrhage (DAH) Rationale for the local mode of action of intra-alveolar human recom-
binant activated factor VII (rFVIIa) in diffuse alveolar hemorrhage (DAH). 
Intravenous rFVIIa does not reach the alveoli in a sufficient concentra-
tion (1) in contrast to the airway route (2). Alveolar tissue factor (TF)-
FVIIa complex activates coagulation factor IX and X. TF and TF pathway 
inhibitor (TFPI) are constitutively expressed in the airspace, secondary 
to inflammation induced in DAH (3). TFPI counteracts the activation 
effect of the FVIIa-TF complex. Alveolar rFVIIa in high concentration 
counteracts the TFPI anticoagulation (4).
Figure 2
Oxygenation capacity before and after local pulmonary human recom- binant activated factor VII (rFVIIa) therapy Oxygenation capacity before and after local pulmonary human recom-
binant activated factor VII (rFVIIa) therapy. A significant improvement in 
PaO2/FiO2 (arterial oxygen pressure/inspiratory fractional oxygen con-
tent) ratio was observed after the hemostatic treatment (*p = 0.024, 
Wilcoxon signed paired rank test).
Key messages
￿  DAH has a high mortality and no documented specific 
intervention.
￿  Symptomatic therapy with local intrapulmonary therapy 
with one or more doses of recombinant FVIIa was found 
to have a good to excellent hemostatic effect in patients 
with DAH.
￿  No adverse effects could be demonstrated.
￿  The treatment with rFVIIa seems to have a high benefit-
to-risk ratio in DAH.Critical Care    Vol 10 No 6    Heslet et al.
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